Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥489.00 JPY
Change Today +1.00 / 0.20%
Volume 17.0K
As of 1:59 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

medicinova inc (4875) Snapshot

Open
¥484.00
Previous Close
¥488.00
Day High
¥490.00
Day Low
¥484.00
52 Week High
06/3/15 - ¥549.00
52 Week Low
07/22/14 - ¥202.00
Market Cap
12.2B
Average Volume 10 Days
47.0K
EPS TTM
¥-0.37
Shares Outstanding
24.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINOVA INC (4875)

Related News

No related news articles were found.

medicinova inc (4875) Related Businessweek News

No Related Businessweek News Found

medicinova inc (4875) Details

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs for the United States market. Its product candidates include MN-166 (Ibudilast), an anti-inflammatory and neuroprotective agent, which has completed Phase II clinical trials for the treatment of neurological disorders; MN-221 (Bedoradrine), a ß2-adrenergic receptor agonist that has completed Phase IIb clinical trails for the treatment of acute exacerbations of asthma; MN-001 (Tipelukast), an orally bioavailable small molecule compound, which has completed a pre-clinical study for the treatment of nonalcoholic steatohepatitis; and MN-029 (Denibulin), a novel tubulin binding agent under development for the treatment of solid tumors. MediciNova, Inc. was founded in 2000 and is based in La Jolla, California.

10 Employees
Last Reported Date: 03/12/15
Founded in 2000

medicinova inc (4875) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $504.8K
Head of Japanese Office and Vice President
Total Annual Compensation: $293.6K
Chief Medical Officer
Total Annual Compensation: $293.6K
Compensation as of Fiscal Year 2014.

medicinova inc (4875) Key Developments

MediciNova Inc. Replaces Ernst & Young LLP with BDO USA, LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2015

The board of directors of MediciNova Inc. recently completed a competitive process to determine what audit firm would serve as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2015. As a result of that process, on June 30, 2015, the company notified Ernst & Young LLP of its dismissal as the company’s independent registered public accounting firm effective as of that date. On June 30, 2015, the company selected BDO USA, LLP as its new independent registered public accounting firm, subject to completion of its standard client acceptance procedures.

MediciNova Inc. Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence

MediciNova Inc. announced that the clinical trial of MN-166 (ibudilast) in alcohol dependence has completed enrollment of 24 subjects. This randomized, double-blind, placebo-controlled study has enrolled 24 non-treatment seeking individuals with either alcohol abuse or dependence in a UCLA research unit. Participants are randomly assigned to a 7-day treatment period involving repeat oral administration of either MN-166 escalated up to 100 mg/day or placebo. During the treatment period, participants will take the study medication, complete an IV alcohol challenge, and will take part in laboratory tests of alcohol craving as well as mood surveys and standard safety tests. Following a 7-10 day study break, trial participants are re-enrolled for another 7-day period wherein they cross over to the other treatment condition. The key study outcomes include safety, tolerability and preliminary efficacy as indicated by whether MN-166 reduces alcohol craving under controlled conditions.

MediciNova Inc. Announces Presentation of Interim Data from Clinical Trial of MN-166 in Alcohol Dependence at the 38th Annual RSA Scientific Meeting

MediciNova Inc. entitled 'A RESEARCH AGENDA ON THE CLINICAL NEUROSCIENCE OF ALCOHOLISM'. At the request of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the sponsor of the study, the presentation included preliminary interim data from the first 22 subjects in the ongoing clinical trial of MN-166 (ibudilast) in alcohol dependence. Dr. Ray commented MN-166 (ibudilast) was very well tolerated and there were no drug-related drop outs or serious adverse events. The preliminary results indicate that ibudilast has beneficial effects on mood (p<0.05), decreased the daily measure of alcohol craving (p=0.05), and potentiated alcohol-induced sedation (p<0.05). This randomized, double-blind, placebo-controlled study will enroll 24 non-treatment seeking individuals with either alcohol abuse or dependence in a UCLA research unit. Participants will be randomly assigned to a 7-day treatment period involving repeat oral administration of either MN-166 escalated up to 100 mg/day or placebo. During the treatment period, participants will take the study medication, complete an IV alcohol challenge, and take part in laboratory tests of alcohol craving as well as mood surveys and standard safety tests. Following a 7-10 day study break, trial participants will re-enroll for another 7-day period wherein they will cross over to the other treatment condition. The key study outcomes include safety, tolerability and preliminary efficacy as indicated by whether MN-166 reduces alcohol craving under controlled conditions. MediciNova licensed MN-166 (ibudilast) from Kyorin Pharmaceutical Co. Ltd. for potential utility in RRMS. Intellectual property was additionally established or obtained by MediciNova in progressive MS and other neurological conditions. MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. It attenuates activated glia cells, which play a major role in certain neurological conditions. Ibudilast's anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical study results and provide the rationale for its therapeutic utility in neurodegenerative diseases (e.g., progressive MS and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease), substance abuse/addiction and chronic neuropathic pain.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4875:JP ¥489.00 JPY +1.00

4875 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4875.
View Industry Companies
 

Industry Analysis

4875

Industry Average

Valuation 4875 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINOVA INC, please visit www.medicinova.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.